NASDAQ:ZBIO Zenas BioPharma (ZBIO) Stock Price, News & Analysis $25.52 +0.67 (+2.67%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Zenas BioPharma Stock (NASDAQ:ZBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Zenas BioPharma alerts:Sign Up Key Stats Today's Range$24.25▼$25.9450-Day Range$24.86▼$33.7752-Week Range$13.50▼$44.60Volume215,673 shsAverage Volume809,264 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$46.71Consensus RatingModerate Buy Company Overview Zenas BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for patients with serious autoimmune diseases. The company’s research is centered on medicines designed to modulate the immune system while potentially avoiding the broad immune-cell depletion associated with some existing treatments. Zenas’ lead product candidate is obexelimab, an investigational monoclonal antibody designed to bind CD19 and FcγRIIb receptors on B cells. Through this mechanism, obexelimab is intended to inhibit B-cell activity without eliminating the cells. The company is evaluating the therapy in immune-mediated diseases, including IgG4-related disease and systemic lupus erythematosus. Zenas BioPharma was established to advance therapies for autoimmune and other immune-mediated conditions and conducts clinical development activities through studies involving patients in multiple geographic regions. The company is headquartered in Waltham, Massachusetts, and its shares began trading on the Nasdaq under the symbol ZBIO in 2024.AI Generated. May Contain Errors. Read More Zenas BioPharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreZBIO MarketRank™: 2.15500327011 of 5 starsZenas BioPharma scored higher than 43% of companies evaluated by MarketBeat, and ranked 659th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingZenas BioPharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialZenas BioPharma has a consensus price target of $46.71, representing about 82.4% upside from its current price of $25.61.Amount of Analyst CoverageZenas BioPharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Zenas BioPharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Zenas BioPharma are expected to grow in the coming year, from ($5.81) to ($4.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Zenas BioPharma is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Zenas BioPharma is -2.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioZenas BioPharma has a P/B Ratio of 5.68. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Zenas BioPharma's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.49% of the float of Zenas BioPharma has been sold short.Short Interest Ratio / Days to CoverZenas BioPharma has a short interest ratio ("days to cover") of 15.48, which indicates bearish sentiment.Change versus previous monthShort interest in Zenas BioPharma has recently increased by 0.59%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthWeak Dividend YieldZenas BioPharma does not currently pay a dividend.Dividend GrowthZenas BioPharma does not have a long track record of dividend growth.Read more about Zenas BioPharma's dividend. News and Social Media2.1 / 5News Sentiment0.32 News SentimentZenas BioPharma has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Zenas BioPharma this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for ZBIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Zenas BioPharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Zenas BioPharma insiders have not sold or bought any company stock.Percentage Held by Insiders22.00% of the stock of Zenas BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsZenas BioPharma has minimal institutional ownership at this time.Read more about Zenas BioPharma's insider trading history. Receive ZBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Zenas BioPharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ZBIO Stock News HeadlinesZenas BioPharma Highlights New Phase 3 Obexelimab DataOctober 14 at 10:46 AM | theglobeandmail.comZenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data ReleaseOctober 13 at 7:29 AM | uk.finance.yahoo.comSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from collapsing — and billionaire Sam Altman is now an investor. This under-the-radar firm is drawing serious attention from those watching the energy infrastructure space closely.October 15 at 1:00 AM | Altimetry (Ad)Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related DiseaseOctober 12 at 7:45 AM | markets.businessinsider.comHead-To-Head Review: MacroGenics (NASDAQ:MGNX) vs. Zenas BioPharma (NASDAQ:ZBIO)October 12 at 5:14 AM | americanbankingnews.comZenas BioPharma, Inc. (ZBIO) - What Are Researchers Saying About This Stock?October 12 at 2:15 AM | americanbankingnews.comZenas Biopharma Inc (ZBIO)October 10, 2026 | investing.comZenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple SclerosisOctober 8, 2026 | marketscreener.comMSee More Headlines ZBIO Stock Analysis - Frequently Asked Questions How have ZBIO shares performed this year? Zenas BioPharma's stock was trading at $36.31 at the beginning of 2026. Since then, ZBIO shares have decreased by 29.5% and is now trading at $25.6050. How were Zenas BioPharma's earnings last quarter? Zenas BioPharma, Inc. (NASDAQ:ZBIO) released its quarterly earnings results on Thursday, August, 13th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by $0.65. The firm earned $1 million during the quarter, compared to the consensus estimate of $15 million. When did Zenas BioPharma IPO? Zenas BioPharma (ZBIO) raised $225 million in an IPO on Thursday, September 12th 2024. The company issued 13,235,294 shares at $16.00-$18.00 per share. How do I buy shares of Zenas BioPharma? Shares of ZBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today10/15/2026Investor update10/27/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ZBIO's financial health is in the Green zone, according to TradeSmith. ZBIO has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ZBIO Previous SymbolNASDAQ:ZBIO CIK1953926 Webzenasbio.com Phone(857) 271-2954FaxN/AEmployees167Year Founded2019Price Target and Rating Average Price Target for Zenas BioPharma$46.71 High Price Target$55.00 Low Price Target$32.00 Potential Upside/Downside+83.0%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($8.99) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$377.74 million Net MarginsN/A Pretax Margin-48,416.40% Return on Equity-122.45% Return on Assets-58.04% Debt Debt-to-Equity Ratio1.57 Current Ratio9.93 Quick Ratio9.93 Sales & Book Value Annual Sales$1 million Price / Sales1,663.32 Cash FlowN/A Price / Cash FlowN/A Book Value$4.51 per share Price / Book5.66Miscellaneous Outstanding Shares65,177,000Free Float50,838,000Market Cap$1.66 billion OptionableN/A Beta-0.90 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ZBIO) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
